About
Peptide Treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalGene Therapy, RNA & Peptide TherapyBoston & New England
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
2
As Collaborator
4
Total Enrollment
297
By Phase
PHASE2: 5PHASE1: 1
By Status
UNKNOWN: 2TERMINATED: 2RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06135103Lead Sponsor
Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
PHASE2Recruiting
50 participants
Started: Nov 26, 2023 · Completed: Sep 30, 2025
NCT06013839Lead Sponsor
TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy
PHASE2Unknown
10 participants
Started: Aug 31, 2023 · Completed: Dec 31, 2024
NCT04401423Collaborator
TXA127 for the Treatment of Severe COVID-19
PHASE2Completed
22 participants
Started: Feb 10, 2021 · Completed: Jun 10, 2021
NCT04605887Collaborator
Angiotensin 1-7 as a Therapy in the Treatment of COVID-19
PHASE2Unknown
120 participants
Started: Jan 18, 2021 · Completed: Apr 30, 2024
NCT01300611Collaborator
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
PHASE1Terminated
20 participants
Started: Jan 31, 2011 · Completed: Dec 31, 2020
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...